Published in final edited form as:

Clin Cancer Res. 2015 April 1; 21(7): 1558–1565. doi:10.1158/1078-0432.CCR-14-0595.

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase 1 Consortium Report

Maryam Fouladi¹, John P. Perentesis¹, Lars M. Wagner¹, Alexander A. Vinks¹, Joel M. Reid², Charlotte Ahern³, George Thomas⁴, Carol A. Mercer⁴, Darcy A. Krueger¹, Peter J. Houghton⁵, L. Austin Doyle⁶, Helen Chen⁶, Brenda Weigel⁷, and Susan M. Blaney⁸

¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH

²Mayo Clinic College of Medicine, Rochester, MN

³Children's Oncology Group Operations Center, Arcadia, CA

⁴University of Cincinnati, Cincinnati, OH

⁵Nationwide Children's Hospital, Columbus, OH

⁶Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

⁷University of Minnesota, Minneapolis, MN

⁸Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX

Abstract

Purpose—To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors.

Experimental Design—Cixutumumab and temsirolimus were administered intravenously once every 7 days in 28 day cycles. Pharmacokinetic and biology studies, including assessment of mTOR downstream targets in peripheral blood mononuclear cells, were performed during the first cycle.

Results—Thirty-nine patients, median age 11.8 years (range, 1–21.5), with recurrent solid or CNS tumors were enrolled of who 33 were fully assessable for toxicity. There were four dose levels, which included two dose reductions and a subsequent intermediated dose escalation: (1) IMC-A12 6 mg/kg, temsirolimus 15 mg/m²; (2) IMC-A12 6 mg/kg, temsirolimus 10 mg/m²; (3) IMC-A12 4 mg/kg, temsirolimus 8 mg/m² and (4) IMC-A12 6 mg/kg, temsirolimus 8 mg/m². Mucositis was the predominant DLT. Other DLTs included: hypercholesterolemia, fatigue,

Corresponding author: Maryam Fouladi, M.D., Division of Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. Telephone: (513) 803-0721; Telefax: (513) 636-3549; maryam.fouladi@cchmc.org cc: pubs@childrensoncologygroup.org.

Presented in part at the American Society of Clinical Oncology, Chicago, IL, June 2012

ClinicalTrials.gov Identifier: NCT00217412

thrombocytopenia, and increased ALT. Target inhibition (decreased S6K1 and PAkt) in PBMNCs was noted at all dose levels. Marked interpatient variability in temsirolimus PK parameters was noted. At 8 mg/m², the median temsirolimus AUC was 2946 ng•h/mL (range, 937–5536) with a median sirolimus AUC of 767 ng•h/mL (range, 245–3675).

Conclusions—The recommended pediatric phase II doses for the combination of cixutumumab and temsirolimus are 6 mg/kg and 8 mg/m², respectively.

Keywords

Phase I trial; temsirolimus; cixutumumab

INTRODUCTION

Deregulated insulin-like growth-factor signaling through the type 1 receptor is common to many childhood solid tumors(1) including Ewing sarcoma,(2) rhabdomyosarcoma,(3) osteosarcoma,(4, 5) neuroblastoma,(6–8) brain tumors,(9–13) Wilms tumor(14) and hepatoblastoma.(15) Similarly, the cell signaling pathways that activate the mammalian target of rapamycin (mTOR) are altered in many pediatric cancers, making them susceptible to mTOR inhibition by sirolimus and its analogs.(16–18) Although we have previously shown preclinical activity of mTOR inhibitors in pediatric cancers,(17) monotherapy with these agents has had limited clinical activity.(16, 19) This may, in part, be explained by a feedback loop in which inhibition of mTOR signaling leads to upregulation of IGF-1R signaling through loss of S6K1 phosphorylation, leading to activation of PI3K and Akt.(20), (21),(22) Indeed, Akt activation has been demonstrated in cancer cell lines and in patients treated with mTOR inhibitors.(23) IGF-1R inhibition should prevent rapamycin-induced Akt activation hence abrogating at least one survival pathway and synergizing with mTOR inhibitors.(20),(21) (24)

Cixutumumab (IMC-A12) is a fully recombinant IgG1 monoclonal antibody that specifically targets the human IGF-IR1 with high affinity. It acts as an antagonist of IGF-1 and IGF-2 ligand binding and signaling. It also blocks ligand binding to IGF-IR and inhibits downstream signaling of the two major insulin-like growth factor pathways: MAPK and PI3K/AKT. Cixutumumab has potent dose-dependent *in vitro* and *in vivo* anti-tumor activity in a variety of cell-lines and xenografts.

Temsirolimus is a small molecule inhibitor of mTOR. Like sirolimus and everolimus, temsirolimus forms a gain-of-function complex with FK506-binding protein 12 (FKBP12) that binds and inhibits mTOR, leading to antiproliferative effects, including G1-phase cell cycle arrest,(25) and apoptosis. The primary downstream targets of mTOR include eIF4E binding protein (4E-BP1) (26) (27) and p70S6 kinase, important in the translation regulation of mRNA encoding proteins involved in G1 phase progression. mTOR inhibitors have potent *in vitro* activity against many human cancer cell lines and xenograft models. The Pediatric Preclinical Testing Program(28),(29) and others have reported preclinical single agent and synergistic combination activity of these agents in many solid tumors.(24),(30, 31)

We report the results of a phase I trial of cixutumumab in combination with temsirolimus in children with recurrent or refractory solid tumors. The primary objectives were to estimate the maximum tolerated dose (MTD), determine dose-limiting toxicities (DLTs) and characterize the pharmacokinetics of IMC A12 and temsirolimus administered once weekly in combination, to children with refractory solid tumors. The secondary objectives were to assess the biological activity of temsirolimus by measuring levels of phospho-S6^{Ser235/236}, phospho-AKT^{Ser473}, and phospho-4EBP1^{Ser65} in peripheral blood mononuclear cells (PBMNCs).

PATIENTS AND METHODS

Patient Eligibility

Patients > 12 months and < 22 years with measurable or evaluable solid tumors refractory to therapy were eligible. Histologic verification of malignancy was required except for patients with intrinsic brainstem glioma. Other eligibility criteria included: Lansky or Karnofsky score ≥ 50 ; recovery from the acute toxic effects of prior therapy; ≥ 3 months since total body irradiation, craniospinal or hemi-pelvic radiation and ≥ 2 months since a stem cell transplant; adequate bone marrow function [peripheral absolute neutrophil count (ANC) $\geq 1000/\mu\text{L}$, platelets $\geq 100,000/\mu\text{L}$ (transfusion independent), hemoglobin ≥ 8.0 g/dL]; adequate renal function (age-adjusted normal serum creatinine or a GFR ≥ 70 mL/min/1.73m²); adequate liver function [total bilirubin $\leq 1.5\times$ institutional upper limit of normal for age, SGPT (ALT) $\leq 5\times$ institutional upper limit of normal for age and albumin ≥ 2 g/dL]; PT and INR $< 1.2 \times$ upper limit of normal. Patients receiving corticosteroids had to be on a stable or decreasing dose for ≥ 7 days prior to study enrollment.

Patients were excluded if they had known bone marrow involvement; had received prior temsirolimus or monoclonal antibody therapy targeting IGF-1R; were pregnant or lactating; had an uncontrolled infection; were receiving enzyme inducing anticonvulsants (EIACD), insulin, growth hormone therapy, or any of the following CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort or other non-cytotoxic anticancer agents. Also excluded were patients with a history of allergic reactions attributed to compounds of similar chemical or biological composition to cixutumumab or temsirolimus, or patients who had undergone major surgery within 6 weeks prior to study enrollment. The Institutional Review Boards of participating institutions approved the protocol. Informed consent and assent, as appropriate, were obtained according to local institutional guidelines.

Drug Administration

Cixutumumab [5 mg/mL (250 mg) or 10 mg/mL (500 mg) vials] and temsirolimus (25 mg/mL), supplied by the Cancer Therapy Evaluation Program (NCI, Bethesda, MD), were administered weekly as a 1 hour and 30 minute infusion, respectively in 28 day cycles. In the absence of disease progression, patients could receive a total of twenty-five cycles of therapy.

The starting dose of cixutumumab was 6 mg/kg (one dose level below the recommended phase II dose of 9 mg/kg) in the pediatric phase I study) (32) and of temsirolimus was 15 mg/m², with planned dose escalations to a maximum of 9 mg/kg for cixutumumab and 35 mg/m² for temsirolimus. The starting dose of temsirolimus was based on published studies in adult combination trials.(33) Due to toxicity, the study was amended to incorporate several dose de-escalations as shown in Table 1.

Trial Design

Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (<http://ctep.cancer.gov/forms/CTCAEv3.pdf>). Hematologic DLT was defined as grade 4 neutropenia for > 7 days, or prior to drug administration on days 8,15 or 21; platelet count <20,000/mm³ on 2 separate days or requiring platelet transfusions on 2 separate days within a 7 day period, or myelosuppression that caused a delay of 14 days between treatment cycles. Non-hematological DLT was defined as grade 3 or 4 non-hematological toxicity with the specific exclusion of: grade 3 nausea and vomiting of < 3 days duration, grade 3 transaminase elevations that returned to Grade 1 or baseline prior to the time for the next treatment cycle, grade 3 fever or infection, non-hematological toxicity that caused a delay of 14 days between treatment cycles.

Any patient who experienced DLT at any time during protocol therapy was considered fully evaluable for toxicity. Patients without DLT who received at least 85% of the prescribed dose during the first 28-day cycle were considered evaluable for toxicity as well as response. Dose escalation proceeded using a modified 3 + 3 cohort design in which three patients were initially studied at each dose level. If none of these three patients experience DLT, the dose was escalated to the next higher level. If one of three patients experienced DLT, then up to three more patients were accrued at the same dose level. If none of these three additional patients experienced DLT, then the dose was escalated. If one or more of these three additional patients experience DLT the MTD was exceeded, unless one of the DLTs did not appear to be related to dose or the DLTs were of different classes and the toxicities were readily reversible. In that circumstance, the cohort could be expanded to 12. The MTD was the maximum dose at which fewer than one third of patients experienced DLT. Once the MTD for the combination was defined up to 6 patients with recurrent or refractory solid tumors were to be enrolled to acquire additional PK data in patients < 12 years.

Response Evaluation

Disease evaluations were obtained at baseline, at the end of cycle 1 and after every other cycle. Tumor response was reported using the Response Evaluation Criteria in Solid Tumors (RECIST).(34)

Pharmacokinetics Studies

Blood samples (5 mLs) for PK analysis of cixutumumab were obtained prior to administration on days 1, 8, 15, 22 and 28 of cycle 1, and days 15 and 28 of cycle 2. In patients who agreed to have additional PK sampling, 3 mLs of blood were collected at the end of the day 1 infusion, and 1, 3, 6 and 24 (± 2) hours, and 4 days (± 1 day) after the first dose. All blood samples were collected at a site distant from the infusion, in tubes without

anticoagulant, allowed to clot at room temperature, centrifuged at 1500 rpm for 15 minutes and stored at less than -20°C . A validated ELISA (enzyme-linked immunosorbent assay) was used to quantify levels of cixutumumab as previously described.(32)

Blood samples (1 mL) for PK analysis of temsirolimus were obtained prior to temsirolimus administration on days 1 and 28 of cycle 1, and days 15 and 28 of cycle 2. In patients who agreed to have additional PK sampling, blood was collected prior at the end and at 15 minutes, 30 minutes, 1, 3, 6, 24 (± 2) hours after the infusion on day 1. All blood samples were collected at a site distant from the infusion.

Temsirolimus and sirolimus concentrations were determined using validated isotope-dilution HPLC-tandem mass spectrometry assays based on previously described principles. (35)

The maximum plasma concentration (C_{max}) and time to maximum plasma concentration (T_{max}) were determined by visual inspection of the plasma concentration-time profiles for subjects participating in the extended PK sampling. Temsirolimus clearance (CL), steady-state volume of distribution (V_{dss}), half-life ($t_{1/2}$) and area under the plasma concentration vs. time curve (AUC_{0-24} and $\text{AUC}_{0-\infty}$) were analyzed using standard non-compartmental methods (NCA, Phoenix WinNonlin, Pharsight Corp, Mountain View, CA). Sirolimus PK parameter estimates for $t_{1/2}$ and $\text{AUC}_{0-\infty}$ were generated using model-based Bayesian analysis (MW/Pharm (Version 3.60, Medware, Groningen, Netherlands). (36)

Biological Assays

Whole blood (4 mLs) was collected in BD Vacutainer CPT sodium citrate tubes prior to administration of protocol therapy on days 1,8, and 28 of cycle 1 in consenting patients. Within 1 hour of acquisition, PBMNC lysate was prepared as described,(37) snap-frozen in liquid nitrogen, and stored at -80°C until phosphoprotein analysis. Phosphorylated and total S6K1, Akt, and 4E-BP1 detection and quantification were performed via Western blot analysis followed by densitometric analysis with ImageQuant 5.0 (Molecular Dynamics, Sunnyvale, CA). The ratio of phosphorylated protein to total (phosphorylated and unphosphorylated) protein in each patient sample was then calculated.

RESULTS

Of 39 patients enrolled, all were eligible, six were not fully assessable for toxicity: two never received protocol therapy because of clinical deterioration, two experienced progressive disease during cycle 1, and two withdrew consent for non-dose limiting toxicities [grade 2 ALT/AST ($n=1$) and grade 2 mucositis ($n=1$)]. Table 2 summarizes the characteristics of the eligible patients. Patients received a median of 2 cycles (range, 1–20) of therapy.

Toxicity

Table 1 summarizes the DLTs across all dose levels. At the starting dose [cixutumumab (6 mg/kg); temsirolimus (15 mg/m^2)], one patient in the initial cohort of three had dose-limiting hypercholesterolemia (grade 3). The cohort was expanded to include three more evaluable patients, one of whom had dose-limiting mucositis (grade 3). Since the observed

DLTs observed were readily reversible, of different classes and unrelated to dose, the statistical design allowed enrollment of up to six additional patients at this dose level. Three different DLTs were observed among this expanded cohort of 6 (grade 3 ALT, fatigue and prolonged thrombocytopenia > 14 days), resulting in a dose de-escalation. At dose level 0 [cixutumumab (6 mg/kg); temsirolimus (10 mg/m²)], 1/3 patients experienced grade 3 dose-limiting mucositis. Three additional patients were enrolled; one of whom experienced grade 3 dose-limiting mucositis. As a result, the protocol was amended to incorporate dose level -1 in which the doses of both agents were further decreased [cixutumumab, (4 mg/kg) and temsirolimus at (8 mg/m²)]. None of the patients at dose level -1 experienced a DLT. An intermediate dose level [cixutumumab (6 mg/kg) and temsirolimus (8 mg/m²)] was subsequently added and one of six patients experienced grade 3 mucositis; none of 6 patients experienced a DLT among an expanded cohort for children < 12 years.

Table 3 summarizes all non-dose-limiting toxicities at least possibly attributable to cixutumumab or temsirolimus in the 33 patients fully assessable for toxicity.

Responses

One partial response, confirmed on central review, was observed following cycle 1 in a patient with medulloblastoma enrolled at dose level 1. Unfortunately, tumor progression was noted on surveillance imaging studies performed after cycle 4. Stable disease for 3 cycles, was observed in three patients (median 12 cycles, range: 11–20) with epithelioid sarcoma, neuroblastoma and alveolar rhabdomyosarcoma, respectively.

Pharmacokinetics

Cixutumumab single-dose pharmacokinetics were studied in 19 patients and steady-state pharmacokinetics were studied in 36 patients who received the combination of cixutumumab with temsirolimus. There were no changes in cixutumumab clearance as the temsirolimus dose was increased (Table 4). The median weight-adjusted clearance and half-life values for all patients were 0.17 ml/hr/kg (range, 0.07–0.43 ml/hr/kg) and 122 hr (range, 64–446 hr), respectively. Cixutumumab serum trough concentrations (C_{trough}) exhibited marked inter-patient variability, increased throughout the first cycle of treatment (Supplemental Figure 1) and a median C_{trough} of approximately 200 µg/ml was achieved on day 28 following a 6 mg/kg dose (Supplemental Table 1). The median cixutumumab C_{trough} at the recommended phase 2 dose was 197 µg/ml (range, 60–544).

Results of the pharmacokinetic data (n=19) following the first dose of temsirolimus at 8, 10 and 15 mg/m²/dose are summarized in Table 5. There was marked inter-patient and inter-dose group variability. Sirolimus, the metabolite of temsirolimus, exposure did not appreciably increase with dose. The steady-state volume of distribution (V_{ss}) was large and increased with dose, ranging from 46.3 L (after 8 mg/m² dose) to 74.9 L (after 15 mg/m² dose). Similarly, temsirolimus clearance from whole blood increased with increasing dose, from 2.3 L/h after an 8 mg/m² dose to 6.7 L/h after a 15 mg/m² dose.

mTOR Pathway Activity

At the recommended phase 2 dose, a total of 23 PBMNC samples were obtained from 9 consenting patients. Four patients had suitable samples from the day 1, 8 and 28 timepoints, three had samples from days 1 and 8, and one had samples from days 1 and 28. Baseline variation in total S6K1 protein was observed among patients, but intra-patient levels were consistent at each time point (days 1, 8, and 28). Phospho-S6K1 (T389) was reduced at day 8 in the seven evaluable patients when compared to baseline (day 1), and in the majority of cases was further reduced at day 28; in only one patient was S6K1 phosphorylation higher at day 28 when compared to baseline. Unlike S6K1, total and phospho-4EPB1 (S65) followed expression levels at each time point, with no observed change in phosphorylation as a function of treatment on day 8 or day 28. Akt phosphorylation (S473) was more variable than S6K1, showing a reduction at day 8 in five patients, and slight or no increase in two others. By day 28, Akt phosphorylation in the five evaluable patients remained variable, with evidence of an increase in three patients, and decrease in the other two, when compared to baseline. Figure 1 depicts a western blot of representative patient PBMNC samples showing inhibition of target proteins p-S6K1 T389 and p-AKT S473.

Discussion

The recommended pediatric phase II doses of the combination of cixutumumab and temsirolimus in children with refractory solid tumor are 6 mg/kg and 8 mg/m², respectively. Similar to adults, observed DLTs included mucositis, fatigue, hypercholesterolemia and transaminitis. However, the MTD of temsirolimus for this combination in children was significantly lower than observed in adults with advanced cancers, (38) relapsed Ewing sarcoma (39) (cixutumumab 6 mg/kg IV and temsirolimus 25 mg flat dose [14 mg/m²]) or metastatic prostate cancer (cixutumumab 6 mg/kg IV and temsirolimus 20 mg flat dose [11 mg/m²]).(40) It was noted in the prostate cancer trial that the weekly schedule was difficult to maintain long-term due to chronic toxicities. Pharmacokinetic data were not available for any of the adult trials. Interestingly, in the adult trials, grade 3 mucositis was observed in 3 to 27% of patients.(38–40) In our study, 4 of 27 patients or 15% experienced grade 3 mucositis, leading to repeated dose de-escalations of the temsirolimus and cixutumumab dose.

Although the pharmacokinetics of cixutumumab (32) and temsirolimus (41) have been previously reported in single agent pediatric studies, this is the first description of the disposition of these drugs when used in combination in children. Cixutumumab clearance, C_{max} and half-life at 6 mg/kg when combined with temsirolimus at the MTD of 8 mg/m² were similar to those reported earlier in the pediatric phase I single agent study of cixutumumab.(32) Furthermore, cixutumumab half-life and steady-state trough concentrations of 122 hours and 197 mg/mL, respectively, at 6 mg/kg were similar to the values of 209 hours and 145 mg/mL reported for adults at that same dose. (42)

Although there was large inter-patient and inter-dose variability in pharmacokinetic parameter estimates for temsirolimus and its active metabolite sirolimus, the temsirolimus and sirolimus AUCs did not increase significantly with dose, which has previously been reported.(43, 44) The steady-state volume of distribution (V_{ss}) of temsirolimus was

generally large, increased with dose, and ranged from 230 L (after a 25-mg dose) to as high as 900 L (after a 250-mg dose). The distribution of temsirolimus into red blood cells appeared to be saturable at higher doses. Additionally, the clearance from whole blood increased with increasing dose, as observed with V_{ss} , with mean values ranging from 20 L/h after a 25-mg dose to 100 L/h after a 250-mg dose (coefficient of variation, approximately 16%–27%).(44) We compared the PK parameters in the pediatric single agent temsirolimus phase I trial to the current study. Spunt et al reported no MTD for temsirolimus at dose levels ranging from 10–150 mg/m².(41) The median temsirolimus C_{max} and AUC values at the MTD of 8 mg/m² in our study, were comparable to median values reported at the 25 and 75 mg/m² dose level reported by Spunt et al. By contrast, the sirolimus AUC and C_{max} were substantially lower in our study at similar doses, with lower sirolimus to temsirolimus ratios at all dose levels tested. The AUCs and C_{max} of temsirolimus, AUCs and C_{min} of sirolimus and cixutumumab observed concentrations did not show an association with toxicity or inhibition of target. The lower MTD observed in this study is possibly pharmacodynamic in nature and related to the combination of IGF-1R and m-TOR inhibition, but requires further evaluation in a larger patient cohort. As these inhibitors affect signaling pathways that regulate glucose, lipid and energy metabolism, it is possible that children may be biologically more sensitive to these drugs, particularly in combination; however, this determination would require further evaluation in a larger patient cohort.

We demonstrated that this combination significantly inhibited the phosphorylation of S6K1, but not 4E-BP1 in PBMNCs at all dose levels. Phospho-S6K1 was reduced at day 8 in the 7 patients with evaluable samples, and was further reduced in 4 of 5 patients with samples at day 28. Although S6K1 and 4E-BP1 are both downstream effectors of mTORC1, these data are consistent with reports that in some cells, rapamycin and the rapalogs are incomplete inhibitors of mTORC1, affecting S6K1 phosphorylation more strongly than 4E-BP1.(45) Similar to previous pediatric and adult reports,(41,46) the phosphorylation status of S6K1, 4E-BP1 and Akt did not correlate with objective responses or prolonged stabilization of disease, limiting their use as biomarkers. There was considerable variation in Akt phosphorylation on days 8 and 28, with either an increase or decrease in Akt phosphorylation when compared to baseline. The pAkt variability is consistent with an earlier pediatric temsirolimus study that demonstrated a lack of correlation between temsirolimus dose and phosphorylation of Akt, S6, and 4E-BP1.(41) However, in the current study, phosphorylation trends of the mTORC1 targets S6K1 and 4E-BP1 were consistently decreased or unchanged, respectively. In five patients, Akt S473 phosphorylation was generally decreased in response to treatment, paralleling S6K1 phosphorylation and consistent with the inhibition of mTOR complex 2 (mTORC2) observed in cells exposed to long term treatment with rapamycin.(47) This decrease may also reflect the efficacy of cixutumumab, but the contribution of IGF-1R signaling to PI3K and Akt may be minor in PBMNCs. In two patients, there was an inverse correlation between pS6K1 (decreased) and pAkt (increased), which may be explained by temsirolimus-mediated inhibition of the mTORC1-S6K1 negative feedback loop, (48–50) leading to increased PI3K signaling to Akt. The variability of pAkt among patients does not appear to correlate with the magnitude of S6K1 inhibition, but instead may be due to a multitude of factors that are patient-specific, including variability in the makeup of the lymphocytes and monocytes in the PBMNC

population, and unknown changes in the status of the immune system following prolonged treatment with temsirolimus and cixutumumab.

This study demonstrates that the combination of cixutumumab and temsirolimus can be safely given to children with recurrent solid tumors, albeit at lower doses than in adult combination studies. One patient with a medulloblastoma had a confirmed partial response and 3 patients experienced prolonged disease stabilization for 3 cycles. Target inhibition was noted in PBMCs at all dose levels as evidenced by a decrease in phosphor-S6K1 and pAKT. A phase II study of this combination has recently been completed in children with recurrent tumors in the Children's Oncology Group.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Melissa Asman for excellent technical assistance as well as Biljana Georgievska, Thalia Beeles, and Mark Ingle of the COG Phase 1/Pilot Consortium Coordinating Center for outstanding administrative and data management support throughout the development and conduct of this trial.

Supported by National Cancer Institute grant No. U01 CA97452 and UM1 CA097452-11

References

1. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. *Oncologist*. 2009; 14:83–91. [PubMed: 19126579]
2. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. *Cancer Res*. 1996; 56:4570–4. [PubMed: 8840962]
3. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. *Cancer Res*. 2008; 68:8039–48. [PubMed: 18829562]
4. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. *Cancer Res*. 1994; 54:2803–7. [PubMed: 8168113]
5. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. *J Surg Oncol*. 1998; 69:21–7. [PubMed: 9762887]
6. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. *J Clin Invest*. 1989; 84:829–39. [PubMed: 2547840]
7. El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. *J Clin Invest*. 1991; 87:648–57. [PubMed: 1991849]
8. van Golen CM, Schwab TS, Kim B, Soules ME, Su Oh S, Fung K, et al. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. *Cancer Res*. 2006; 66:6570–8. [PubMed: 16818629]
9. Sun Q, Wei X, Feng J, Zhang R, Shen Q, Dong J, et al. Involvement of insulin-like growth factor-insulin receptor signal pathway in the transgenic mouse model of medulloblastoma. *Cancer Sci*. 2008; 99:234–40. [PubMed: 18271920]

10. Del Valle L, Enam S, Lara C, Ortiz-Hidalgo C, Katsetos CD, Khalili K. Detection of JC polyomavirus DNA sequences cellular localization of T-antigen and agnoprotein in oligodendrogliomas. *Clin Cancer Res.* 2002; 8:3332–40. [PubMed: 12429619]
11. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. *Oncogene.* 2001; 20:3857–68. [PubMed: 11439349]
12. Del Valle L, Enam S, Lassak A, Wang JY, Croul S, Khalili K, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. *Clin Cancer Res.* 2002; 8:1822–30. [PubMed: 12060623]
13. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. *Neoplasia.* 2005; 7:7–16. [PubMed: 15720813]
14. Gansler T, Allen KD, Burant CF, Inabnett T, Scott A, Buse MG, et al. Detection of type 1 insulinlike growth factor (IGF) receptors in Wilms' tumors. *Am J Pathol.* 1988; 130:431–5. [PubMed: 2831722]
15. Gray SG, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P, et al. Altered expression of members of the IGF-axis in hepatoblastomas. *Br J Cancer.* 2000; 82:1561–7. [PubMed: 10789725]
16. Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. *J Clin Oncol.* 2007; 25:4806–12. [PubMed: 17947729]
17. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. *Pediatr Blood Cancer.* 2007
18. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. *Nat Rev Cancer.* 2004; 4:335–48. [PubMed: 15122205]
19. Spunt SL, Grupp S, Vik T. Phase I, safety, pharmacokinetic, exploratory biomarker study of intravenous temsirolimus in children with advanced solid tumors. *American Society of Pediatric Hematology Oncology.* 2007
20. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res.* 2006; 66:1500–8. [PubMed: 16452206]
21. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. *Mol Cancer Ther.* 2005; 4:1533–40. [PubMed: 16227402]
22. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. *Oncogene.* 2007; 26:1932–40. [PubMed: 17001314]
23. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. *PLoS Med.* 2008; 5:e8. [PubMed: 18215105]
24. Kurmasheva RT, Boltz C, Phelps D, et al. Human monoclonal antibody CP751871 combined with rapamycin is effective treatment for childhood sarcomal xenografts. 2008
25. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature.* 1994; 369:756–8. [PubMed: 8008069]
26. Lin TA, Kong X, Haystead TA, Pause A, Belsham G, Sonenberg N, et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. *Science.* 1994; 266:653–6. [PubMed: 7939721]
27. Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, et al. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. *Proc Natl Acad Sci USA.* 1995; 92:7222–6. [PubMed: 7638171]

28. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. *Pediatr Blood Cancer*. 2008; 50:799–805. [PubMed: 17635004]
29. Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. *Pediatr Blood Cancer*. 2012; 58:729–35. [PubMed: 21630428]
30. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. *Cell*. 1992; 69:1227–36. [PubMed: 1377606]
31. Kurihara M, Tokunaga Y, Tsutsumi K, Kawaguchi T, Shigematsu K, Niwa M, et al. Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma. *J Neurosurg*. 1989; 71:538–44. [PubMed: 2552046]
32. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol*. 2012; 30:256–62. [PubMed: 22184397]
33. Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, et al. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. *Breast Cancer Res Treat*. 2013; 139:145–53. [PubMed: 23605083]
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000; 92:205–16. [PubMed: 10655437]
35. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. *Journal of chromatography B, Biomedical sciences and applications*. 2000; 748:41–53.
36. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. *Computers in biology and medicine*. 1992; 22:155–63. [PubMed: 1617949]
37. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. *Cancer Res*. 2004; 64:252–61. [PubMed: 14729632]
38. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. *Clin Cancer Res*. 2011; 17:6052–60. [PubMed: 21750201]
39. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. *Clin Cancer Res*. 2012; 18:2625–31. [PubMed: 22465830]
40. Rathkopf DEDDC, Morris MJ, Slovin SF, Borwick LS, Momen L, Curley T, Arauz G, Larson SM, Fleisher M, Rosen N, Scher HI. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study. *J Clin Oncol*. 2011; 29 (suppl; abstr e15081) 2011;29.
41. Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. *J Clin Oncol*. 2011; 29:2933–40. [PubMed: 21690471]
42. McKian KP, Haluska P. Cixutumumab. *Expert Opin Investig Drugs*. 2009; 18(7):1025–33.
43. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. *J Clin Pharmacol*. 2007; 47:1430–9. [PubMed: 17913896]

44. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. *J Clin Oncol*. 2004; 22:909–18. [PubMed: 14990647]
45. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. *Science*. 2010; 328:1172–6. [PubMed: 20508131]
46. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Ditttrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. *J Clin Oncol*. 2005; 23:5314–22. [PubMed: 15955899]
47. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell*. 2006; 22:159–68. [PubMed: 16603397]
48. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. *Trends Cell Biol*. 2001; 11:437–41. [PubMed: 11684411]
49. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature*. 2004; 431:200–5. [PubMed: 15306821]
50. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, et al. DGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. *J Clin Invest*. 2007; 117:730–8. [PubMed: 17290308]

Statement of Relevance

Deregulated insulin-like growth-factor signaling through the type 1 receptor is common to many childhood solid tumors. Similarly, the cell signaling pathways that activate the mammalian target of rapamycin (mTOR) are altered in many pediatric cancers. IGF-1R inhibition should prevent rapamycin-induced Akt activation hence abrogating at least one survival pathway and synergizing with mTOR inhibitors. This first pediatric phase I combination study established the recommended pediatric phase II doses for cixutumumab and temsirolimus at 6 mg/kg and 8 mg/m², respectively with mucositis as the dose limiting toxicity. Target inhibition (decreased p-S6K1 and p-Akt) in peripheral blood mononuclear cells (PBMNCs) was noted at all dose levels. One partial response was reported in a medulloblastoma patient; prolonged stable disease was noted in 3 patients (median: 12 cycles). These results lay the groundwork for additional combination studies with IGFR and mTOR inhibitors. A phase II study of this combination has recently been completed by the COG.

Figure 1. Western blot of representative patient samples showing inhibition of target proteins pS6K1 T389 and pAKT S473 along with the respective total protein. Samples were taken before the first dose was administered (1) and on day 8 and 28 post treatment.

Table 1

Dose-limiting toxicity (DLT)

Dose Level	IMC-A12 (mg/kg)	Temsirolimus (mg/m ²)	Number of Patients Entered	Number of Patients Evaluable	Number of Patients with DLT	Type of DLT (n)
1	6	15	15	12	5	Platelets (1), Fatigue (1), Mucositis (1), ALT (1), Hypercholestermia (1)
0	6	10	6	6	2	Mucositis/stomatitis (2)
-1	4	8	4	3	0	
Intermediate	6	8	8	6	1	Mucositis (1)
Expanded PK cohort	6	8	6	6	0	

Table 2

Characteristics of Eligible Patients (n=39)

Characteristic	Number
Age (years) Median (Range)	11.8 (1.0–21.5)
Male:Female	20 (51%) : 19 (49%)
Diagnosis	
Rhabdomyosarcoma	9
Osteosarcoma	6
Ewing sarcoma	5
Malignant Glioma (including GBM)	4
Medulloblastoma	2
Wilms Tumor	2
Desmoplastic small round cell tumor	2
Astrocytoma NOS	1
Choroid plexus papilloma	1
Neuroblastoma	1
Neurilemmoma	1
Ganglioneuroblastoma	1
Gastrointestinal stromal tumor	1
Hepatocellular carcinoma	1
Atypical teratoid rhabdoid tumor	1
Epithelioid Sarcoma	1
Prior Therapy	
Chemotherapy regimens : Median (Range)	2 (0–7)
Prior Radiotherapy	28

Table 3
Non-Dose Limiting toxicities related to protocol therapy observed in evaluable patients (n=33)

Toxicity Type	Maximum grade of toxicity across cycle 1 (total, 33 cycles)				Maximum grade of toxicity across cycles 2 to 20 (Total, 77+22 follow-up cycles)			
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Hematologic								
Anemia	11	2	3		5	7		
Lymphocyte count decreased	11	4	1	1	8	2	2	
Neutrophil count decreased	3	7	3	1	3	4	1	
Platelet count decreased	17	3	4		9	1	2	
White blood cell decreased	8	6	2		6	3	2	
Non-Hematologic*								
Alanine aminotransferase increased	9	2			3	3	1	
Aspartate aminotransferase increased	6	2			4	3		
Cholesterol high	13	2			5	1		
Constipation	3	1						
Creatinine increased	4				1			
Fatigue	7	1			4			
Headache	5	1			2			
Hyperglycemia	15	6			6	6		
Hypermagnesemia	4				2			
Hypertiglyceridemia	14	4			7	3		
Hypocalcemia	6	1			4			
Hypokalemia	4				3			
Hyponatremia	5				5			
Hypophosphatemia	7	2	3		1	2	2	
Mucositis oral	5	5			3	1	2	
Nausea	6	3			3	1	1	
Proteinuria	1	3				1		
Rash acneiform	5	1						

Toxicity Type	Maximum grade of toxicity across cycle 1 (total, 33 cycles)				Maximum grade of toxicity across cycles 2 to 20 (Total, 77+22 follow-up cycles)			
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Weight loss	5	1			1	2		

* Non-hematologic toxicities are those that occurred in > 10% of patients as determined in the first cycle of therapy

Table 4

Summary of Cycle 1 IMC-A12 Pharmacokinetic (PK) Parameters

IMC-A12 Dose Tensiolimus Dose	6 mg/kg 8 mg/m ² (n=8)		6 mg/kg 10 mg/m ² (n = 3)		6 mg/kg 15 mg/m ² (n = 4)	
	Median	Range	Median	Range	Median	Range
C _{max} (µg/mL)	281	(239–355)	277	(219–390)	230	(161–464)
T _{max} (h)	2.0	(1.0–7.0)	1.1	(1.1–2.2)	2.1	(1.1–7.0)
t _{1/2} (h)	98	(64–161)	122	(88–133)	130	(98–446)
AUC _{0–7d} (h•µg/L)	20.6	(11.6–29.7)	25.6	(20.6–28.7)	26.4	(14.8–34.0)
CL (mL/h)	8.3	(1.1–15.2)	9.9	(2.9–14.5)	7.0	(3.1–14.3)
CL (mL/h/kg)	0.19	(0.12–0.43)	0.17	(0.12–0.18)	0.13	(0.07–0.24)
V _{dss} (mL)	1050	(150–2390)	1750	(470–1840)	1860	(590–2400)
V _{dss} (mL/kg)	25.8	(20.8–40.3)	22.7	(20.7–29.4)	31.1	(18.6–42.3)

Table 5

Summary of Cycle 1 Pharmacokinetic Data for Temsirolimus and its Metabolite

Temsirolimus Dose	8 mg/m ² (n=11)		10 mg/m ² (n = 3)		15 mg/m ² (n = 5)	
	Median	Range	Median	Range	Median	Range
Temsirolimus						
C _{max} (ng/mL)	509	187-2010	606	283-675	660	615-1310
T _{max} (h)	0.8	0.5-1.2	0.7	0.6-1.3	0.6	0.5-0.7
CL (L/h)	2.3	1.1-8.2	5.5	1.5-11.4	6.7	5.5-24.7
V _{dss} (L)	46.3	6.2-124.5	50.4	40.5-68.1	74.9	18.4-99.6
t _{1/2} (h)	10.3	5.3-45.9	10.5	3.8-18.4	10.3	7.3-12.9
AUC _{0-24h} (h•ng/mL)	2022	698-5194	2654	1650-2975	2784	973-4028
AUC _{inf} (h•ng/mL)	2946	937-5536	3646	1666-4820	3274	973-5293
Sirolimus						
C _{max} (ng/mL)	20.3	3.4-83.2	21.3	10.2-28.1	32.3	21.4-38.5
T _{max} (h)	1.6	1.0-6.5	1.7	1.3-1.7	1.0	0.8-1.2
t _{1/2} (h)	51.0	25.4-126.8	68.9	60.8-71.0	70.9	15.3-123.5
AUC _{0-24h} (h•ng/mL)	273	77-1252	285	160-353	579	220-661
AUC _{inf} (h•ng/mL)*	767	245-3675	1268	551-3210	2870	1850-5563
Sum AUC _{T+S} (h•ng/mL)	5750	1182-8932	4914	4876-5371	6446	2823-8464
Ratio Sir/Tem	0.3	0.1-1.7	0.3	0.1-1.9	1.0	0.5-1.9

Inf = form time zero to infinity (0-∞)